



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

August 27, 2021

Thomas Freeburg  
Chief Financial Officer  
Interpace Biosciences, Inc.  
Morris Corporate Center 1, Building C  
300 Interpace Parkway  
Parsippany, NJ 07054

**Re: Interpace Biosciences, Inc.**  
**Form 10-K for the Fiscal Year Ended December 31, 2020**  
**Filed April 1, 2021**  
**File No. 000-24249**

Dear Mr. Freeburg:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences